Management of Cancer Therapy–Related Cardiac Dysfunction: A Case-Based Review

Abstract

With an ever-expanding repertoire of cancer therapies, cardiologists increasingly encounter patients with cancer therapy–related cardiac dysfunction. This can range from asymptomatic mild left ventricular dysfunction to severe symptomatic congestive heart failure. A multidisciplinary approach involving oncologists and cardiologists is needed in the management of these patients. This case-based review provides a practical guide for clinicians regarding the diagnosis and management of cancer therapy–related cardiac dysfunction associated with commonly used cancer treatments: anthracyclines, human epidermal receptor 2–targeted therapies, and immune checkpoint inhibitors.